This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hennessy, B.T. Articles by Breathnach, O.S. Search for Related Content PubMed PubMed Citation Articles by Hennessy, B.T. Articles by Breathnach, O.S.

Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer

^a Department of Medical Oncology, Cork University Hospital, Cork, Ireland; ^b Department of Medical Oncology, Mater Misericordiae Hospital, Dublin, Ireland; ^c Mercy University Hospital, Cork, Ireland

Correspondence: Bryan Hennessy, M.D., Department of Medical Oncology, Cork University Hospital, Wilton, Cork, Ireland. Telephone: 353-85-722-7666; Fax: 353-21-492-1346; e-mail: bryanhen{at}gofree.indigo.ie

Combination chemotherapy has been shown to improve overall survival compared with best supportive care in patients with advanced non-small cell lung cancer (NSCLC). The survival advantage is modest and was initially demonstrated with cisplatin-containing regimens in a large meta-analysis of randomized trials reported in 1995. Newer chemotherapy combinations have been shown to be better tolerated than older cisplatin-based combinations, and some trials have also shown greater efficacy and survival benefits with these newer combinations. Combination chemotherapy is, therefore, the currently accepted standard of care for patients with good performance statuses aged less than 70 years with advanced NSCLC. However, there are limited data from clinical trials to support the use of combination chemotherapy in elderly patients over 70 years of age with advanced NSCLC. Subgroup analyses of large randomized phase III trials suggest that elderly patients with good performance statuses do as well as younger patients treated with combination chemotherapy. There are few randomized trials reported that evaluate chemotherapy in patients aged greater than 70 years only. Based on data from trials performed by an Italian group, single-agent vinorelbine has been shown to have significant activity in elderly patients with advanced NSCLC and to be well tolerated by those patients with Eastern Cooperative Oncology Group performance statuses of two or less, with associated improvements in measures of global health.

Key Words. Non-small cell lung cancer • Chemotherapy • Vinorelbine • Gemcitabine • Elderly

This article has been cited by other articles:

				M. B. Rodin and S. G. Mohile A Practical Approach to Geriatric Assessment in Oncology J. Clin. Oncol., May 10, 2007; 25(14): 1936 - 1944. [Abstract] [Full Text] [PDF]

				R. R. Jennens, R. de Boer, L. Irving, D. L. Ball, and M. A. Rosenthal Differences of Opinion: A Survey of Knowledge and Bias Among Clinicians Regarding the Role of Chemotherapy in Metastatic Non-small Cell Lung Cancer Chest, December 1, 2004; 126(6): 1985 - 1993. [Abstract] [Full Text] [PDF]